Literature DB >> 29446085

DR4 mediates the progression, invasion, metastasis and survival of colorectal cancer through the Sp1/NF1 switch axis on genomic locus.

Shenshen Wu1, Qingtao Meng1, Chengcheng Zhang1, Hao Sun1, Runze Lu1, Na Gao2, Hongbao Yang3, Xiaobo Li1, Michael Aschner4, Rui Chen1,5.   

Abstract

The single nucleotide polymorphism (SNP), -397G > T (rs13278062) polymorphism, in the promoter of Death Receptor 4 (DR4) had been reported to be associated with a significantly increased risk for bladder cancer. However, the association of this SNP with the risk of colorectal cancer has not been reported. In this study, we performed a case-control study in 1,078 colorectal cancer patients and 1,175 matched healthy controls to evaluate the association of the potential functional genetic variants in DR4 with risk and survival of colorectal cancer. PCR-TaqMan were used to genotype the rs13278062, rs1000294 and rs2235126 polymorphisms. We found that subjects carrying the rs13278062 GT/TT genotypes had a significantly lower risk and increased survival time when compared to the GG genotype. We also constructed the rs13278062 GT/TT genotype in SW480 and SW620 cells (rs13278062 is GG in both cell lines) with the CRISPR/Cas9 system. Flow cytometry experiments showed that the rs13278062 TT genotype promoted apoptosis in colorectal cancer cells. In vitro and in vivo experiments established that the rs13278062 G to T mutation inhibited carcinogenesis and metastasis of colorectal cancer. Chromatin immunoprecipitation (ChIP) assays revealed that the rs13278062 G > T polymorphism altered the binding affinity of the transcription factors Sp1/NF1 to the rs13278062 mutation region. Immunohistochemistry, western blot, and qPCR corroborated that the rs13278062 GT/TT genotypes increased the expression of DR4 protein in colorectal cancer tissues and cells. In conclusion, these findings indicate that DR4 mediated progression, invasion, metastasis and survival of colorectal cancer via the Sp1/NF1 switch axis on genomics locus.
© 2018 UICC.

Entities:  

Keywords:  DR4; colorectal cancer; development; survival

Mesh:

Substances:

Year:  2018        PMID: 29446085     DOI: 10.1002/ijc.31318

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Astragalus mongholicus Bunge-Curcuma aromatica Salisb. suppresses growth and metastasis of colorectal cancer cells by inhibiting M2 macrophage polarization via a Sp1/ZFAS1/miR-153-3p/CCR5 regulatory axis.

Authors:  Junfei Gu; Ruolan Sun; Decai Tang; Fuyan Liu; Xiangwei Chang; Qiaohan Wang
Journal:  Cell Biol Toxicol       Date:  2022-01-24       Impact factor: 6.819

2.  MPO Promoter Polymorphism rs2333227 Enhances Malignant Phenotypes of Colorectal Cancer by Altering the Binding Affinity of AP-2α.

Authors:  Qingtao Meng; Shenshen Wu; Yajie Wang; Jin Xu; Hao Sun; Runze Lu; Na Gao; Hongbao Yang; Xiaobo Li; Boping Tang; Michael Aschner; Rui Chen
Journal:  Cancer Res       Date:  2018-03-14       Impact factor: 12.701

3.  Association between polymorphism in the promoter region of lncRNA GAS5 and the risk of colorectal cancer.

Authors:  Yajie Wang; Shenshen Wu; Xi Yang; Xiaobo Li; Rui Chen
Journal:  Biosci Rep       Date:  2019-04-16       Impact factor: 3.840

4.  Association between nucleotide excision repair gene polymorphism and colorectal cancer risk.

Authors:  Yujie Zhang; Shenshen Wu; Xiumei Zhou; Fang Huang; Rui Chen; Yigang Wang; Jiong Wu
Journal:  J Clin Lab Anal       Date:  2019-09-30       Impact factor: 2.352

5.  CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer.

Authors:  Hongbao Yang; Xiaobo Li; Qingtao Meng; Hao Sun; Shenshen Wu; Weiwei Hu; Guilai Liu; Xianjing Li; Yong Yang; Rui Chen
Journal:  Mol Cancer       Date:  2020-01-23       Impact factor: 27.401

6.  MAGI2-AS3 rs7783388 polymorphism contributes to colorectal cancer risk through altering the binding affinity of the transcription factor GR to the MAGI2-AS3 promoter.

Authors:  Xi Yang; Shenshen Wu; Xiaobo Li; Ying Yin; Rui Chen
Journal:  J Clin Lab Anal       Date:  2020-06-12       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.